Glucagon-like peptide-1 (GLP-1) receptor agonists have shown consistent neuroprotective and metabolic effects in both preclinical and early clinical studies of AD, improving synaptic plasticity, mitochondrial function, and insulin signaling [33]. Here, INS is linked to Alzheimer disease.